Kaftrio (Tezacaftor, Elexacaftor, Ivacaftor)

The combination contains two correctors (tezacaftor and elexacaftor) that assist the misfolded CFTR protein to reach the cell surface, and a potentiator (ivacaftor) that enhances the channel’s opening. Together they restore chloride transport across epithelial cells, addressing the root cause of cystic fibrosis.

The specific dose and dosing schedule of Kaftrio are determined by the prescribing healthcare professional based on the patient’s age, weight, genotype and clinical condition. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for Kaftrio in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss them with women of childbearing potential. Breastfeeding decisions should also be made in consultation with a medical professional.

To request Kaftrio, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kaftrio combines two correctors with a potentiator, offering a broader mutation coverage than some earlier modulators that contain only a single corrector. Clinical studies suggest comparable or improved efficacy in lung function and reduction of exacerbations for patients with at least one F508del allele, while safety profiles remain similar.

Kaftrio tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and excessive heat. Keep the container tightly closed and out of reach of children. No special refrigeration is required.

Kaftrio is taken orally as a tablet, usually with a glass of water. The medication may be taken with or without food, but patients should follow the instructions given by their prescriber to maintain consistent absorption and therapeutic effect.

Serious adverse events include hepatitis, cataract formation, and severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for liver enzyme elevations, undergo periodic eye examinations, and report any signs of rash, swelling, or breathing difficulty immediately.

Kaftrio is contraindicated in individuals with known hypersensitivity to any of its components. Caution is also advised for patients with severe liver disease, active cataracts, or those taking strong CYP3A inducers or inhibitors without appropriate medical supervision.